Table I.
Patient characteristics related to aeroallergen testing among 1,412 adults with asthma
| Characteristic | Overall (n = 1,412) | No testing (n = 728) | Testing (n = 684) | P value |
|---|---|---|---|---|
| Age | <.001 | |||
| 18-34 years | 444 (31.4) | 183 (25.1) | 261 (38.2) | |
| 35-44 years | 257 (18.2) | 114 (15.7) | 143 (20.9) | |
| 45-54 years | 247 (17.5) | 144 (19.8) | 103 (15.1) | |
| 55-64 years | 226 (16.0) | 135 (18.5) | 91 (13.3) | |
| 65+ years | 238 (16.9) | 152 (20.9) | 86 (12.6) | |
| Sex | .35 | |||
| Male | 308 (21.8) | 166 (22.8) | 142 (20.7) | |
| Female | 1,104 (78.2) | 562 (77.2) | 542 (79.2) | |
| Race | <.001 | |||
| American Indian or Alaskan Native | 8 (0.6) | 0 (0.0) | 8 (1.2) | |
| Asian | 65 (4.6) | 33 (4.5) | 32 (4.7) | |
| Black | 517 (36.6) | 232 (31.9) | 285 (41.7) | |
| Native Hawaiian or other Pacific Islander | 1 (0.1) | 0 (0.0) | 1 (0.1) | |
| White | 821 (58.1) | 463 (63.6) | 358 (52.3) | |
| Ethnicity | .02 | |||
| Not Hispanic or Latino | 1,377 (97.5) | 717 (98.5) | 660 (96.5) | |
| Hispanic or Latino | 35 (2.5) | 11 (1.5) | 24 (3.5) | |
| Insurance | <.001 | |||
| Commercial | 716 (50.7) | 358 (49.2) | 358 (52.3) | |
| Medicaid | 375 (26.6) | 170 (23.4) | 205 (30.0) | |
| Medicare | 321 (22.7) | 200 (27.5) | 121 (17.7) | |
| BMI | .84 | |||
| Normal | 407 (28.8) | 220 (30.2) | 187 (27.3) | |
| Overweight | 413 (29.2) | 207 (28.4) | 206 (30.1) | |
| Class I obesity | 265 (18.8) | 136 (18.7) | 129 (18.8) | |
| Class II obesity | 158 (11.2) | 80 (11.0) | 78 (11.4) | |
| Class III obesity | 169 (12.0) | 85 (11.7) | 84 (12.3) | |
| Smoking category | .23 | |||
| Never | 965 (68.3) | 483 (66.3) | 482 (70.5) | |
| Former | 322 (22.8) | 178 (24.5) | 144 (21.0) | |
| Current | 125 (8.9) | 67 (9.2) | 58 (8.5) | |
| COPD | 111 (7.9) | 57 (7.8) | 54 (7.9) | .96 |
| Chronic rhinitis | 1,328 (94.1) | 652 (89.6) | 676 (98.8) | <.001 |
| Inhaler category in the 12-month period before the index visit | .14 | |||
| No ICS | 724 (51.3) | 352 (48.4) | 372 (54.4) | |
| ICS only | 195 (13.8) | 110 (15.1) | 85 (12.4) | |
| ICS/LABA | 412 (29.2) | 223 (30.6) | 189 (27.6) | |
| ICS/LABA and LAMA | 81 (5.7) | 43 (5.9) | 38 (5.6) | |
| OCS bursts in the 12-month period before the index visit | .70 | |||
| 0 | 930 (65.9) | 484 (66.5) | 446 (65.2) | |
| 1 | 282 (20.0) | 138 (19.0) | 144 (21.1) | |
| 2-3 | 149 (10.6) | 77 (10.6) | 72 (10.5) | |
| 4 or more | 51 (3.6) | 29 (4.0) | 22 (3.2) | |
| Asthma ED visit in the 12-month period before the index visit | 36 (2.5) | 16 (2.2) | 20 (2.9) | .39 |
| Asthma hospitalization in the 12-month period before the index visit | 21 (1.5) | 10 (1.4) | 11 (1.6) | .72 |
| Step-up therapy after the index visit | 491 (34.8) | 234 (32.1) | 257 (37.6) | .03 |
Data are presented as nos. (%). Patients who did not receive any testing (n = 728) were compared with patients who received any SPTs or serum-specific IgE tests on or within 90 days of index allergy/immunology visit (n = 684) by chi-square test.